​

​

​

​

LONGWOOD HEALTHCARE LEADERS WINTER WEBCONFERENCE | AGENDA | JANUARY 6-7, 2022

​

THURSDAY, JANUARY 6, 2022

​

7:00 am PT / 10:00 am ET | LONGWOOD FUND INTRODUCTION

Christoph Westphal, General Partner, Longwood Fund

​

7:30 am PT / 10:30 am ET | NEWCO TO ESTABLISHED: BUILDING A BIOTECH

Phil Johnson, CEO, Interius Biotherapeutics; Rahul Kakkar, former CEO, Pandion Therapeutics; Mark McKenna, CEO, Prometheus Bio; Catherine Sohn, Chair, BioEclipse Therapeutics; David Southwell, CEO, TScan Therapeutics

Moderator: Luba Greenwood, CEO, Kojin Therapeutics

​

8:00 am PT / 11:00 am ET | BIG BIOPHARMA R&D
Philip Larsen, Global Head of Research and Early Development, Bayer; Shiva Malek, Global Head, Oncology, Novartis; Andy Plump, President, R&D, Takeda; Rupert Vessey, President, Research and Early Development, Bristol Myers Squibb 

Moderator: Luigi Gentile, CRO, BenchSci

​

8:30 am PT / 11:30 am ET | STANFORD MEDICINE: ACCELERATING THE TRANSLATION OF DISCOVERIES
Marc Tessier-Lavigne, President, Stanford; Lloyd Minor, Dean, Stanford Medicine

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

8:50 am PT / 11:50 am ET | REGULATORY AND INDUSTRY ROUNDTABLE

Janet Woodcock, Acting Commissioner, FDA; John Maraganore, Former Founding CEO, Alnylam; Dave Ricks, CEO, Eli Lilly

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

9:10 am PT / 12:10 pm ET | EXPEDITING RESEARCH FOR TREATMENTS AND CURES

Christopher Coburn, Chief Innovation Officer, Mass General Brigham; Ray Deshaies, SVP, Research, Amgen; Raj Devraj, CEO, Rectify Pharma; Brian McVeigh, CEO, Code Biotherapeutics; Chen Schor, Chair, Carbon Bio

Moderator: Colin Hill, CEO, GNS Healthcare

​

9:40 am PT / 12:40 pm ET | SOURCING AND IDENTIFYING NOVEL TECHNOLOGY

Annalisa D'Andrea, President & CSO, ImmuneID; Pearl Huang, CEO, Cygnal Therapeutics; Jeremy Levin, CEO, Ovid Therapeutics; Ankit Mahadevia, CEO, Spero Therapeutics; Matthew Porteus, Scientific Founder, Graphite Bio

Moderator: Beth Shafer, Head, Neuroscience, Drug Discovery Sciences, & Externalization BD, Takeda

​

10:10 am PT / 1:10 pm ET | FIRESIDE CHAT
Jay Bradner, President, Novartis Institutes for BioMedical Research; Julie Gerberding, Chief Patient Officer, Merck; former Director, CDC; Dave Reese, EVP, R&D, Amgen

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

10:30 am PT / 1:30 pm ET | INNOVATION IN CELL THERAPY
Jeff Bluestone, CEO, Sonoma Biotherapeutics; Jessica Flechtner, CSO, Genocea; Pascal Touchon, CEO, Atara Biotherapeutics; Krishnan Viswanadhan, President & COO, Be Bio

Moderator: Jak Knowles, CEO, Affini-T

​

11:00 am PT / 2:00 pm ET | CULTIVATING AN ECOSYSTEM OF PARTNERS  

Al Beardsley, COO, Galera; Pratap Khedkar, CEO, ZS Associates; Kabir Nath, CEO, Otsuka US; Rafaèle Tordjman, CEO, Jeito 

Moderator: Michal Preminger, Head, East North America, Johnson & Johnson Innovation

​

11:30 am PT / 2:30 pm ET | FIRESIDE CHAT

Anne Klibanski, President & CEO, Mass General Brigham; Josh Sharfstein, Vice Dean, Public Health Practice & Community Engagement, Johns Hopkins Bloomberg School of Public Health

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

11:50 am PT / 2:50 pm ET | HOW M&A SPURS INNOVATION 

Mark Enyedy, CEO, ImmunoGen; Henry Ji, CEO, Sorrento Therapeutics; Rachna Khosla, SVP, BD, Amgen; Stuart Mackey, Global Head, BD, Daiichi Sankyo

Moderator: Chad Shear, Principal, Fish & Richardson

​

12:20 pm PT / 3:20 pm ET | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA

Ken Drazan, CEO, ArsenalBio; Chaitan Khosla, Director, Innovative Medicines Accelerator, Stanford; Bob Langer, Co-Founder, Momenta; Paul Schimmel, Professor, Cell & Molecular Biology, Scripps; Brian Thomas, CEO, Metagenomi

Moderator: Joel Marcus, Executive Chair, Alexandria Real Estate Equities/ Alexandria Venture Investments

​

12:50 pm PT / 3:50 pm ET | ADVANCING PLATFORM TECHNOLOGIES

Paul Blake, CEO, Papyrus Therapeutics; Sarah Boyce, CEO, Avidity Bio; Steve Potts, CEO, OncoMyx Therapeutics; Carlo Russo, CMO & Head of Development, Genenta; Joanne Smith-Farrell, CEO, Be Bio

Moderator: Jim Scibetta, CEO, ImmuneID

​

1:20 pm PT / 4:20 pm ET | FIRESIDE CHAT

Henry Gosebruch, Chief Strategy Officer, AbbVie; Bob Langer, Co-Founder, Momenta

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

1:40 pm PT / 4:40 pm ET | DRUG APPROVALS: INSIGHTS, OUTLOOK, AND COMMITMENT TO PATIENTS

Thomas Lonngren, former Executive Director, EMA; Rich Moscicki, CMO & EVP, Science & Regulatory Advocacy, PhRMA; Mike Rosenblatt, Senior Partner & CMO, Flagship Pioneering; Clay Siegall, CEO, SeaGen; Zhen Su, CEO, Marengo Therapeutics

Moderator: Belen Carillo-Rivas, Global Head, Regulatory Affairs, Saniona

​

2:10 pm PT / 5:10 pm ET | MAKING A BIG IMPACT WITH LIMITED RESOURCES

Bobby Azamian, CEO, Tarsus Therapeutics; Kerrie Brady, CEO, OcuTerra Therapeutics; Mary Fisher, CEO, Colorescience; Christer Rosén, CEO, Jupiter Neurosciences; Andrew Sternlicht, CEO, Aisa Pharma; Neil Weir, CEO, Sitryx

Moderator: Chip Clark, CEO, Genocea

​

2:40 pm PT / 5:40 pm ET | ACCELERATING DRUG DEVELOPMENT

Tina Albertson, CMO, Lyell Immunopharma; Charlie Albright, CSO, Affinia Therapeutics; Amit Etkin, CEO, Alto Neuroscience; Bill Hinshaw, CEO, Axcella Therapeutics

Moderator: John Westwood, Partner & Global Life Sciences Business Leader, Oliver Wyman

​

3:10 pm PT / 6:10 pm ET | MAKING SMART INVESTMENTS

Ansbert Gadicke, Managing Partner, MPM Capital; Arjun Goyal, Managing Director, Vida Ventures; Sophie Kornowski, Senior Partner, Gurnet Point Capital

Moderator: Kyle Lefkoff, General Partner, Boulder Ventures

​

3:40 pm PT / 6:40 pm ET | LONGWOOD FUND SUMMARY

Aleks Radovic-Moreno, Partner, Longwood Fund

​

FRIDAY, JANUARY 7, 2022

​

7:00 am PT / 10:00 am ET | LONGWOOD FUND INTRODUCTION

David Steinberg, General Partner, Longwood Fund

​

7:30 am PT / 10:30 am ET | PLACING PATIENTS AT THE CENTER

Mike Devoy, CMO, Bayer; Ruxandra Draghia Akli, Global Head, Global Public Health R&D, Janssen; Melanie Goldey, COO & CFO, TMRW Life Science; Eileen Maus, CEO, Renovia; Armon Sharei, CEO, SQZ Biotech

Moderator: Will Lewis, CEO, Insmed

​

8:00 am PT / 11:00 am ET | FIRESIDE CHAT: GOING THE DISTANCE FOR PATIENT CARE: LEADING FROM THE FRONT

Greg Divis, CEO, Avadel Pharmaceuticals; Christi Shaw, CEO, Kite Pharma

Moderator: Julie Kampf, CEO, JBK Associates International

​

8:20 am PT / 11:20 am ET | LEVERAGING MACHINE LEARNING AND NEW TECH

Paul Belcher, Global Product Strategy Manager, Cytiva; Lee Chae, CTO, Brightseed Bio; William Greene, CEO, Fountain Therapeutics; Iya Khalil, Global Head, AI Innovation Center, Novartis; Brian Martin, Head, AI, AbbVie; Karen Nelson, CSO, Thermo Fisher Scientific

Moderator: Sean McClain, CEO, Absci

8:50 am PT / 11:50 am ET | R&D COLLABORATION

Hafrun Fridriksdottir, EVP, Global R&D, Teva Pharmaceuticals; Jim List, Global Therapeutic Area Head, Cardiovascular, Metabolism, & Retina, Janssen Pharmaceuticals; Deepak Srivastava, President, Gladstone Institutes; Skip Virgin, EVP, Research & CSO, Vir Bio

Moderator: Bill Mezzanotte, EVP, Head, R&D, CSL Behring

​

9:20 am PT / 12:20 pm ET | SPOTLIGHT: STANFORD INNOVATION

Alyce Adams, Stanford Medicine Innovation Professor, Stanford; Catherine Blish, Professor of Medicine, Infectious Diseases, Stanford; Bali Pulendran, Professor of Microbiology and Immunology, Stanford

​Moderator: Carolyn Bertozzi, Baker Family Director of Stanford ChEM-H, Stanford

​

9:50 am PT / 12:50 pm ET | NOVEL THERAPEUTIC MODALITIES

Manuel Aivado, CEO, Aileron Therapeutics; Grace Colon, CEO, Incarda; David Gifford, Founder, ThinkTx; Jessica Grossman, CEO, IgGenix; Bahija Jallal, CEO, Immunocore; Reenie McCarthy, CEO, Stealth BioTherapeutics; Tamas Oravecz, CSO, Parthenon Therapeutics

Moderator: James Sapirstein, CEO, First Wave BioPharma

​

10:20 am PT / 1:20 pm ET | FIRESIDE CHAT

Hal Barron, Head, R&D, GlaxoSmithKline; Levi Garraway, EVP, Head, Global Product Development, CMO, Roche

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

10:40 am PT / 1:40 pm ET | RE-DESIGNING PARTNERING  

Gerald Commissiong, CEO, Todos Medical; Matthias Müllenbeck, SVP, Head, Global BD & Alliance Management, Merck KGaA; Nauman Shah, Global Head, BD, Janssen; Chris Viehbacher, Managing Partner, Gurnet Point Capital

Moderator: Mark Barrett, CEO, Lassen Therapeutics

​

11:10 am PT / 2:10 pm ET | DEVELOPING A WORLD-CLASS BOARD

Nima Farzan, CEO, Kinnate Biopharma; Vanessa King, CEO, Tenpoint Therapeutics; Arlene Morris, former CEO, Syndax Pharmaceuticals; David Pyott, former CEO, Allergan, Inc.

Moderator: Pamela Contag, CEO, BioEclipse Therapeutics

​

11:40 am PT / 2:40 pm ET | FIRESIDE CHAT

Steve Hahn, former Commissioner, FDA; Mathai Mammen, , EVP, Pharmaceuticals R&D, Johnson & Johnson

Moderator: Christoph Westphal, General Partner, Longwood Fund

​

12:00 pm PT / 3:00 pm ET | CLINICAL TRIAL DIVERSITY

Jung Choi, Chief Business and Strategy Officer, Global Blood Therapeutics; Al Gianchetti, CEO, XyloCor; Lynn Kramer, Chief Clinical Officer, Eisai; Maria Rivas, CMO, Merck KGaA

Moderator: Sharon Karlsberg, Principal, ZS Associates

​

12:30 pm PT / 3:30 pm ET | FINANCING INNOVATION

Peter Bisgaard, Managing Director, Nan Fung Life Sciences; Chris Garabedian, CEO, Xontogeny; Ursheet Parikh, Partner, Mayfield

Moderator: Katherine Andersen, Head, Life Science & Healthcare, Silicon Valley Bank

​

1:00 pm PT / 4:00 pm ET | FIRESIDE CHAT

Jeremy Levin, CEO, Ovid Therapeutics; Clay Siegall, CEO, Seagen

Moderator: David Steinberg, General Partner, Longwood Fund

​

1:20 pm PT / 4:20 pm ET | R&D TRANSFORMATION

Amy Abernethy, President, Clinical Studies Platforms, Verily; Robert Blum, CEO, Cytokinetics; David Meek, CEO, Mirati; David Weinreich, EVP, Head, Global Clinical Development, Regeneron

Moderator: Glenn Gormley, Executive Chair, Daiichi Sankyo

​

1:50 pm PT / 4:50 pm ET | THE NEXT WAVE OF FINANCINGS: IPOS, REVERSE MERGERS, SPACS

 Brian Frenzel, CEO, Tosk; Matt McIlwain, Managing Director, Madrona; Brian Silver, CFO, TScan Therapeutics

Moderator: Chris Cortis, COO, Tectonic Therapeutics  

​

2:20 pm PT / 5:20 pm ET | FIRESIDE CHAT

Bob Nelsen, Managing Director, ARCH Venture Partners; Chris Viehbacher, Managing Partner, Gurnet Point Capital

Moderator: Christoph Westphal, General Partner, Longwood Fund

2:40 pm PT / 5:40 pm ET | NOVEL APPROACHES TO DRUG DISCOVERY

Stewart Campbell, CEO, Axial Therapeutics; Larry Hamann, Global Head, Drug Discovery Sciences, Takeda; Sharath Hegde, CSO, Herophilus; Cigall Kadoch, Associate Professor, Pediatric Oncology, Dana-Farber Cancer Institute

Moderator: Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana Farber Cancer Institute

​

3:10 pm PT / 6:10 pm ET | INNOVATIVE PARTNERSHIPS

Bing Chen, Head, Alliances & BD, AstraZeneca; Alban de La Sabliere, SVP, Global Head, Partnering, Sanofi; Heather Schwoebel, COO & CBO, Alloy Therapeutics; Amanda Wagner, CBO, Immunitas

Moderator: Philippe Lopes-Fernandes, CBO, IPSEN

​

3:40 pm PT / 6:40 pm ET | LONGWOOD FUND SUMMARY

Aleks Radovic-Moreno, Partner, Longwood Fund

​

​

Our mission is to create and grow clusters that ignite and accelerate the world's leading innovators in their noble pursuit to advance human health by curing disease and improving nutrition.

For more information, visit: https://www.are.com/

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

For more information, visit: https://www.cytivalifesciences.com/

Fish & Richardson, a premier global intellectual property (IP) law firm, works with pioneering life sciences companies to help them achieve their strategic IP goals through partnering, licensing, financing, acquisition, and enforcement. We do this by bringing a unique, holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP. For more information, visit: https://www.fr.com/

GNS Healthcare is an AI company developing Gemini — The in silico Patient™ models from clinico-genomic data across oncology, auto-immune diseases, and neurology. In silico patients allow for clinical trials across cohorts of diverse patients to be conducted computationally by simulating disease progression and drug response at the individual patient level. GNS’ REFS causal AI and simulation technology integrates and transforms a wide-variety of multi-omic and real-world data to reveal the complex system of interactions underlying disease progression — constructing in silico patients. GNS partners with the world’s leading biopharmaceutical companies and health plans and has validated its science and technology in more than 60 publications and abstracts. For more information, visit: www.gnshealthcare.com

At Oliver Wyman, our thinking and strategic advice helps clients in the payer, provider, digital health, and life sciences sectors realize their most ambitious organizational and operational goals by bridging the gap between their business today and their vision for the future. We are focused on creating positive change in healthcare and have built a community to share and shape ideas that will transform the industry and create a healthcare system that meets the needs of communities and companies. We bring a relentless pursuit of finding a better way to deliver care and solve the industry’s most complex challenges, many of which cut across the payer, provider, and life sciences sectors.  ​For more information, visit: https://www.oliverwyman.com

For nearly 40 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators.  For more information, visit: https://www.svb.com/